The lack of robust BPC-157 human trialsspecifically Phase II and Phase III studiesmeans that definitive conclusions about its efficacy, optimal dosing, and long-term safety in humans cannot be made
Lau, J., Bloch, P., Schffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L.B., McGuire, J., Steensgaard, D.B., Strauss, H.M., Gram, D.X., Knudsen, S.M., Nielsen, F.S., Thygesen, P., Reedtz-Runge, S., & Kruse, T
In some cases, a systemic approach may be taken depending on your overall goals
54, 10631075.10.1111/j.1365-313X.2008.03477.x 17 HellR.BergmannL